Silence Therapeutics Reveals Encouraging Preliminary Results at 36 Weeks from Active Phase 2 Trial with Zerlasiran in Subjects with Elevated Lipoprotein(a) Levels.

Deciphering CCR8 Activation and Inhibition Mechanisms: Genentech's Findings in Nature Communications.

Takeda Reveals Encouraging Initial Outcomes of Phase 2 Trial for Mezagitamab (TAK-079), an Emerging Leading Anti-CD38 Monoclonal Antibody, in Treating Primary Immune Thrombocytopenia.

Doxepin, the small molecule drug, serves as a cogent therapeutic agent, targeting both the norepinephrine transporter (NET) and serotonin transporter subtype 5 (SERT-5).

Pfizer Reveals Favorable Survival Data from Stage III Study of ADCETRIS® for Recurrent/Resistant Large B-cell Lymphoma Treatment.

clinical-stage biopharma atai Life Sciences (NASDAQ: ATAI), focused on transforming mental health treatment, announced a strategic investment in Beckley Psytech, cementing its position as the bio-pharma leader with the broadest portfolio of clinical-stage psychedelic drug candidates.

At the 2024 AAD conference, Longbio Pharma showcased encouraging early-stage findings for their drug LP-003.

Fenofibrate, the small molecule drug, possesses a unique ability to target the peroxisome proliferator-activated receptor alpha (PPARα) as an agonist.

10xBio Reveals Interim Phase 2b Trial Outcomes Indicate Enhanced Effectiveness of New Treatment in Submental Fat Reduction.

Recently, a collaborative research effort involving multiple German scientific institutions has revealed that the endothelin B receptor (ETB) plays a crucial role in controlling metabolic syndrome brought on by high-calorie diets.

Initial stage of the onCARlytics study focusing on solid cancers moves forward to explore combined therapeutic approaches.

Simvastatin, a diminutive molecular entity, functions as an HMG-CoA reductase enzyme inhibitor, which is accountable for the synthesis of cholesterol in the hepatic tissue.